Although previous studies on everolimus have reported variable rates of hepatitis, the incidence of all-grade and high-grade (grade 3–4, ALT > 5 ULT) ALT elevation has ranged from 11% to 47% and 1.5% to 4%, respectively, with no clear association with tumor type, chemotherapy regimen, or combination therapy [19]. This evidence concerns the gene GPT and Hepatitis.